NCT05489614 - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

October 24, 2023

Study Completion Date

December 19, 2023

Conditions

Renal Impairment

Interventions

DRUG

Olpasiran

Participants will receive olpasiran by subcutaneous (SC) injection.

Trial Locations (6)

Orlando Clinical Research Center, Orlando

Clinical Pharmacology Of Miami, LLC, Miami

Nucleus Network - Minneapolis, Saint Paul

CRSCA HC LLC, dba Creekside Post Acute, Yucaipa

Inland Empire Clinical Trials, LLC, Rialto

Advanced Pharma CR, LLC, Miami